Uday R. Popat, MD

Uday R. Popat, MD, discusses promising findings from a phase 2 trial evaluating the JAK inhibitor itacitinib combined with post-transplant cyclophosphamide and tacrolimus for graft-vs-host disease prevention.

Uday R. Popat, MD, discusses the rationale behind evaluating itacitinib over other JAK inhibitors for graft-vs-host disease prophylaxis in a phase 2 study.

Uday R. Popat, MD, discusses a phase 2 trial exploring the use of itacitinib combined with post-transplant cyclophosphamide and tacrolimus to prevent graft-vs-host disease in patients undergoing a myeloablative fractionated busulfan regimen.

Uday R. Popat, MD, discusses the role of ruxolitinib as treatment of patients with graft-versus-host-disease.